ArticleJournal of psychiatry & neuroscience : JPN2008
Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.
Article in Journal of psychiatry & neuroscience : JPN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.Journal of clinical psychopharmacology · 2010Trial
- DNA methylation and single nucleotide variants in the brain-derived neurotrophic factor (BDNF) and oxytocin receptor (OXTR) genes are associated with anxiety/depression in older women.Frontiers in genetics · 2015Article
- From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2014Review
- Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.Neuroscience · 2013Review
- Personalized medicine in psychiatry: problems and promises.BMC medicine · 2013Review
- Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Mild depressive symptoms, self-reported disability, and slowing across multiple functional domains.International psychogeriatrics · 2012Article
- Review
- Estradiol and progesterone modify the effects of the serotonin reuptake transporter polymorphism on serotonergic responsivity to citalopram.Experimental and clinical psychopharmacology · 2011Article
- Late-life depression: evidence-based treatment and promising new directions for research and clinical practice.The Psychiatric clinics of North America · 2011Review
- Gene-environment interactions in geriatric depression.The Psychiatric clinics of North America · 2011Review
- Upper gastrointestinal bleeding in a patient receiving selective serotonin reuptake inhibitor.BMJ case reports · 2011Article
- Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients.Drugs & aging · 2011Review
- Pharmacogenetics of antidepressant response.Journal of psychiatry & neuroscience : JPN · 2011Review
- Pharmacogenomics of suicidal events.Pharmacogenomics · 2010Review
- The promise and reality of pharmacogenetics in psychiatry.The Psychiatric clinics of North America · 2010Review
- Reliable neuromodulation from circuits with variable underlying structure.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Pharmacogenetics of antidepressant response: an update.Human genomics · 2009Review
- Incomplete response in late-life depression: getting to remission.Dialogues in clinical neuroscience · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate whether variable antidepressant response may be influenced by an interaction between the serotonin transporter promoter polymorphism (5-HTTLPR) and antidepressant concentration.
methodsElderly subjects with depression treated with paroxetine (n = 110) were genotyped and assessed with the Hamilton Rating Scale for Depression (HAMD). A mixed-effect analysis of repeated measures was used.
resultsThere was an interaction between early paroxetine concentration and 5-HTTLPR genotype on symptomatic improvement over 12 weeks (F(18,59.5) = 1.8, p < 0.05), as well as main effects of both paroxetine concentration (F(68,55.3) = 2.4, p < 0.005) and genotype (F(2,74.2) = 5.7, p < 0.005). Paroxetine concentrations were correlated with change in HAMD scores after 2 weeks of treatment in subjects with the short (s) allele (r = 0.31, p < 0.05) but not in subjects homozygous for the long (l) allele.
conclusionThe results demonstrate a concentration-response relation for paroxetine in late-life depression and support the hypothesis for both a direct main effect and a moderating influence of 5-HTTLPR alleles on this concentration-response relation.
Indexed as
Identifiers
18330458PMC2265313W2095762847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.